
The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.
Regulators made significant advancements in treatments for unmet needs and streamlining review processes in May.
Welcome to PharmTech’s Regulatory Roundup for May 2026.






